Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xilio Therapeutics (Nasdaq: XLO), a clinical-stage biotechnology company focused on tumor-activated immuno-oncology therapies, has granted stock options to four new employees. The grants, effective February 1, 2025, consist of non-qualified stock options to purchase 83,400 shares of common stock at an exercise price of $0.705 per share, matching the closing price on January 31, 2025.
The options have a ten-year term with a vesting schedule of 25% after the first year of employment, followed by the remaining 75% vesting in 36 monthly installments. These grants were made under Xilio's 2022 Inducement Stock Incentive Plan as employment inducements in accordance with Nasdaq Listing Rule 5635(c)(4).
Xilio Therapeutics (Nasdaq: XLO), un'azienda biotecnologica in fase clinica focalizzata su terapie immuno-oncologiche attivate dai tumori, ha concesso opzioni su azioni a quattro nuovi dipendenti. Le concessioni, a partire dal 1 febbraio 2025, consistono in opzioni su azioni non qualificate per l'acquisto di 83.400 azioni ordinarie a un prezzo di esercizio di $0,705 per azione, corrispondente al prezzo di chiusura del 31 gennaio 2025.
Le opzioni hanno un termine di dieci anni con un programma di maturazione del 25% dopo il primo anno di impiego, seguito dal restante 75% che matura in 36 rate mensili. Queste concessioni sono state effettuate nell'ambito del Piano di Incentivazione delle Azioni per Induzione 2022 di Xilio come incentivi all’occupazione in conformità con la Regola di Elenco Nasdaq 5635(c)(4).
Xilio Therapeutics (Nasdaq: XLO), una empresa de biotecnología en etapa clínica centrada en terapias de inmuno-oncología activadas por tumores, ha concedido opciones de acciones a cuatro nuevos empleados. Las concesiones, efectivas a partir del 1 de febrero de 2025, consisten en opciones de acciones no calificadas para comprar 83,400 acciones ordinarias a un precio de ejercicio de $0.705 por acción, igualando el precio de cierre del 31 de enero de 2025.
Las opciones tienen un plazo de diez años con un calendario de adquisición del 25% después del primer año de empleo, seguido del 75% restante que se adquirirá en 36 cuotas mensuales. Estas concesiones se realizaron bajo el Plan de Incentivos de Acciones por Inducción 2022 de Xilio como incentivos para empleo de acuerdo con la Regla 5635(c)(4) de Nasdaq.
Xilio Therapeutics (Nasdaq: XLO), 종양 활성화 면역 종양학 치료에 집중하는 임상 단계의 생명공학 회사가 네 명의 신입 직원에게 주식 옵션을 부여했습니다. 이 부여는 2025년 2월 1일부터 효력이 발생하며, 83,400주의 보통주를 주당 $0.705의 행사가격으로 구매할 수 있는 비자격 주식 옵션으로 구성됩니다. 이는 2025년 1월 31일의 종가와 일치합니다.
옵션은 10년의 기간을 가지며, 첫 해 근무 후 25%가 베스팅되고, 나머지 75%는 36개월에 걸쳐 월별 할부로 베스팅됩니다. 이 부여는 Nasdaq 상장 규칙 5635(c)(4)에 따라 고용 유인을 위한 Xilio의 2022년도 유도 주식 인센티브 계획 하에 이루어졌습니다.
Xilio Therapeutics (Nasdaq: XLO), une entreprise de biotechnologie en phase clinique axée sur les thérapies d’immuno-oncologie activées par les tumeurs, a accordé des options d'achat d'actions à quatre nouveaux employés. Les concessions, effectives à partir du 1er février 2025, consistent en des options d'achat d'actions non qualifiées pour l'achat de 83 400 actions ordinaires à un prix d'exercice de 0,705 $ par action, correspondant au prix de clôture du 31 janvier 2025.
Les options ont une durée de dix ans avec un calendrier d'acquisition de 25 % après la première année d'emploi, suivi des 75 % restants qui s’acquièrent en 36 versements mensuels. Ces concessions ont été réalisées dans le cadre du Plan d'Incentives de Stock 2022 de Xilio comme incitations à l'emploi conformément à la règle d'inscription Nasdaq 5635(c)(4).
Xilio Therapeutics (Nasdaq: XLO), ein biotechnologisches Unternehmen in klinischer Phase, das sich auf tumoraktivierte Immunonkologietherapien konzentriert, hat Aktienoptionen an vier neue Mitarbeiter gewährt. Die Gewährungen, die am 1. Februar 2025 in Kraft treten, bestehen aus nicht qualifizierten Aktienoptionen zum Kauf von 83.400 Stammaktien zu einem Ausübungspreis von 0,705 $ pro Aktie, entsprechend dem Schlusskurs am 31. Januar 2025.
Die Optionen haben eine Laufzeit von zehn Jahren mit einem Vesting-Zeitplan von 25 % nach dem ersten Beschäftigungsjahr, gefolgt von den verbleibenden 75 %, die in 36 monatlichen Raten fällig werden. Diese Gewährungen erfolgten im Rahmen des Xilio Aktienanreizplans 2022 als Beschäftigungsanreize gemäß der Nasdaq-Listingregel 5635(c)(4).
- None.
- None.
WALTHAM, Mass., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective February 1, 2025, the company granted non-qualified stock options to purchase an aggregate of 83,400 shares of its common stock to four new employees under Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan.
The stock options have an exercise price of
The stock options are subject to the terms and conditions of Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the grants and were made as an inducement material to each individual entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
About Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecifics and immune cell engagers. Learn more by visiting www.xiliotx.com and follow us on LinkedIn (Xilio Therapeutics, Inc.).
This press release contains hyperlinks to information that is not deemed to be incorporated by reference in this press release.
Investor and Media Contact:
Scott Young
Vice President, Investor Relations and Corporate Communications
investors@xiliotx.com
FAQ
What is the exercise price of XLO stock options granted on February 1, 2025?
How many shares of XLO stock were included in the February 2025 inducement grants?
What is the vesting schedule for XLO's February 2025 inducement stock options?
How long is the term of XLO's February 2025 inducement stock options?
